Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
8 hedge funds and large institutions have $66.8K invested in Virpax Pharmaceuticals, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
432% more capital invested
Capital invested by funds: $12.6K → $66.8K (+$54.3K)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
60% more funds holding
Funds holding: 5 → 8 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$31.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$27.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$19.2K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$12.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$670 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$10.3K |
| 2 |
PA
Parallel Advisors
San Francisco,
California
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $21.8K | +$31.2K | +1,255 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $19.4K | +$27.8K | +1,119 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $14.2K | +$19.2K | +774 | +1,800% |
|
|
TSS
4
Two Sigma Securities
New York
| $8.7K | +$12.4K | +501 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $2.66K | +$670 | +27 | +21% |
|
|
SRCM
6
Signature Resources Capital Management
Newport Beach,
California
| $35 | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $26 | +$25 | +1 | New |
|
8
Morgan Stanley
New York
| $10 | – | – | – |
|
|
WAM
9
Warberg Asset Management
Winnetka,
Illinois
| – | -$10.3K | -800 | Closed |
|
|
PA
10
Parallel Advisors
San Francisco,
California
| – | -$1 | – | – |
|
VRPX Hedge Fund Activity: Q3 2024 in Review
8 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q3 2024, worth a combined $66.8K — up 432% from $12.6K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new VRPX positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $31.2K. The largest seller was Warberg Asset Management, exiting entirely with an estimated $10.3K sold.
- 8 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q3 2024, up from 5 in Q2 2024.
- Funds reported $66.8K of Virpax Pharmaceuticals, Inc. Common Stock stock for Q3 2024, up 432% quarter-over-quarter.
- 4 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q3 2024 and 1 closed out, a net change of +3 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q3 2024 was Citadel Advisors, an estimated $31.2K added.
- The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q3 2024 was Warberg Asset Management, an estimated $10.3K sold.
Based on aggregated 13F filings for Q3 2024.